Agent Description
Nivolumab is a human monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Nivolumab is an IgG4 kappa immunoglobulin that has a calculated molecular mass of 146 kDa.
Mechanism of Action
Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth.
Classification
Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody.
Molecular Target
N/A
Monograph
View the nivolumab package insert (PDF).
Studies of Interest
Areas of Interest
- Non-small cell lung cancer: studies evaluating sequencing, and methods for early assessment of response
- Bladder: studies in various lines of therapy with nivolumab or nivolumab/ipilimumab plus standard of care (BCG, chemo)
- Renal cell carcinoma: nivolumab plus bevacizumab in first line
Areas NOT of Interest
- Nivolumab monotherapy in metastatic melanoma patients
- Nivolumab monotherapy in adjuvant stage 3 melanoma patients (exception is special populations like mucosal and uveal)
- Nivolumab combinations with radiation in melanoma
- Nivolumab plus tyrosine kinase inhibitors in renal cell carcinoma
- Nivolumab/ipilimumab/cabozantinib combination in renal cell carcinoma
- Nivolumab plus sorafenib in hepatocellular carcinoma
- Nivolumab in hepatocellular carcinoma patients potentially eligible for liver transplant
- Nivolumab with epidermal growth factor receptor inhibitors or anaplastic lymphoma kinase inhibitors, or radiation (but interested in nivolumab with novel therapeutics) in non-small cell lung cancer
Information collaborator would like included in investigator proposals
N/A